AstraZeneca to Invest $50 Billion in the U.S. by 2030

AstraZeneca has announced a $50 billion investment in the United States by 2030, creating tens of thousands of new, highly skilled direct and indirect jobs across the country, thereby powering growth and delivering next-generation medicines for patients in America and worldwide.

AstraZeneca joins an expanding cohort of major pharmaceutical companies that have also announced investments in the U.S. this year, including Sanofi, Roche, Gilead, J&J, and Novartis.

About the Investment

The cornerstone of this investment is a new multi-billion dollar U.S. manufacturing facility that will produce drug substances for the Company’s weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new center will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024.

The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca’s largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimize production.

The $50 billion investment over the next five years also includes:

• Expansion of the company’s R&D facility in Gaithersburg, Maryland
• An R&D center in Kendall Square, Cambridge, Massachusetts
• Manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California
• Continuous manufacturing expansion in Mount Vernon, Indiana
• Specialty manufacturing expansion in Coppell, Texas
• New sites to supply clinical trials
• Growing research and development investment in novel medicines

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia’s desire to create highly-skilled jobs in science and technology and will strengthen the country’s domestic supply chain for medicines.”

Earlier this year, AstraZeneca also announced plans to invest $2.5 billion in Beijing to establish another global strategic R&D center.